A robust and durable activity of DNMTi on tumor growth inhibition described by our group is that DAC-treated glioma cells harboring IDH1 mutation and 1p19q co-deletion remain viable, but without evidence of tumor growth onset in mice for 55 days [83]. This evidence concerns the gene IDH1 and central nervous system cancer.